Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/24/2868510/0/en/Avenue-Therapeutics-Announces-Reverse-Stock-Split.html
https://www.globenewswire.com/news-release/2024/03/25/2851621/0/en/Avenue-Therapeutics-to-Host-Virtual-Key-Opinion-Leader-KOL-Event-on-April-4-2024.html
https://www.globenewswire.com/news-release/2024/03/18/2848163/0/en/Avenue-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com/news-release/2024/03/18/2848163/0/en/Avenue-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com//news-release/2024/03/15/2847021/0/en/Avenue-Therapeutics-Receives-Positive-Listing-Determination-from-Nasdaq.html
https://www.globenewswire.com//news-release/2024/03/11/2843690/0/en/Avenue-Therapeutics-to-Present-BAER-101-Preclinical-Data-at-American-Society-for-Experimental-Neurotherapeutics-ASENT-2024-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/22/2833698/0/en/Avenue-Therapeutics-Announces-Publication-in-Drug-Development-Research-Highlighting-First-In-Class-Preclinical-Data-of-BAER-101-in-a-Translational-Model-of-Absence-Epilepsy.html
https://www.globenewswire.com//news-release/2024/01/11/2807852/0/en/Avenue-Therapeutics-to-Present-at-Sidoti-January-Micro-Cap-Investor-Conference.html
https://www.globenewswire.com//news-release/2024/01/05/2804696/0/en/Avenue-Therapeutics-Enters-into-Warrant-Exercise-Transactions-for-5-0-Million-in-Proceeds.html
https://www.globenewswire.com//news-release/2024/01/04/2804007/0/en/Avenue-Therapeutics-Reaches-Final-Agreement-with-the-U-S-FDA-for-the-Phase-3-Safety-Study-for-IV-Tramadol.html